OTC:MRMD
MARIMED INC.
A biopharma innovator developing novel therapies for inflammatory diseases with a focus on US and European markets.
Key Metrics
Investment Thesis
Bull Case
Marimed offers exposure to a growing pipeline of novel therapies for inflammatory diseases with revenue expanding at a compound annual growth rate supported by recent capital investments. If clinical trials succeed, the company could unlock significant value from its current $78.9M equity base and specialized product portfolio.
Bear Case
The company faces substantial financial headwinds with a negative operating profit of -$12.1M and a massive retained earnings deficit of -$112.1M that requires continuous financing. Investors should be wary of the heavy cash outflows in investing activities which could deplete liquidity if product approvals are delayed.
About MARIMED INC.
Marimed Inc. is a biopharmaceutical company focused on developing novel therapies for inflammatory diseases, operating primarily within the United States and Europe markets. The company generates revenue through its specialized pharmaceutical product portfolio aimed at treating conditions like ulcerative colitis and other immune-mediated disorders. Key financial drivers include significant capital expenditures in R&D and manufacturing capabilities to support their clinical pipeline expansion.
Analysis
Management Discussion
While revenue grew to $158M in 2024 from $134M in 2022, the company reported a net loss of $12.1M, narrowing slightly from the prior year's -$16.0M but still reflecting high operating costs against revenue growth. The substantial capital expenditure of $12.0M and negative investing cash flow of -$17.1M suggest aggressive scaling or potential asset restructuring that warrants close monitoring against liquidity levels.
Industry Overview
The biopharmaceutical industry for inflammatory diseases is characterized by high R&D costs and long development cycles, with companies like Marimed competing against established giants and emerging biosimilar entrants. Market growth is driven by aging demographics and increasing prevalence of chronic immune-mediated conditions requiring innovative biologics.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $134.0M | $148.6M | $158.0M |
| Cost of Revenue | $70.1M | $82.7M | $95.1M |
| Gross Profit | $64.0M | $65.9M | $62.9M |
| Operating Expenses | $43.6M | $51.5M | $60.0M |
| Operating Income | $20.4M | $14.4M | $2.9M |
| G&A | $20.7M | $22.1M | $25.6M |
| Stock-Based Comp | — | $1.0M | $1.1M |
| D&A | — | $5.5M | $7.9M |
| Depreciation | $3.4M | $5.5M | $7.9M |
| Amortization | $1.3M | $3.0M | $2.9M |
| Other OpEx | $22.9M | $29.4M | $34.3M |
| Non-Operating Income | $-861.0K | $-21.0M | $-6.9M |
| Interest Expense | $1.7M | $9.2M | — |
| Interest Income | $959.0K | $270.0K | $114.0K |
| Pre-Tax Income | $19.5M | $-6.6M | $-4.0M |
| Income Tax | $5.9M | $9.4M | $8.2M |
| Continuing Ops | $13.6M | $-16.0M | $-12.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $13.6M | $-16.0M | $-12.1M |
| Minority Interest | $146.0K | $24.0K | $37.0K |
| Net to Common | $13.5M | $-16.0M | $-12.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $44.1M | $51.4M | $53.5M |
| Cash & Equivalents | $9.7M | $14.6M | $7.3M |
| Marketable Securities | $123.0K | $88.0K | $0 |
| Accounts Receivable | $4.2M | $7.2M | $8.7M |
| Inventory | $19.5M | $25.3M | $33.5M |
| Other Current Assets | $10.7M | $4.2M | $4.0M |
| Long-Term Assets | $108.1M | $144.7M | $153.5M |
| PP&E (Net) | $71.6M | $89.1M | $94.2M |
| Goodwill | $8.1M | $12.0M | $15.8M |
| Operating Leases | $4.9M | $9.7M | $8.7M |
| LT Investments | $0 | $221.0K | $0 |
| Other LT Assets | $23.4M | $33.7M | $34.8M |
| Total Assets | $152.2M | $196.1M | $207.0M |
| Current Liabilities | $26.5M | $30.9M | $48.7M |
| Accounts Payable | $6.6M | $9.0M | $13.2M |
| Current Leases | $1.3M | $1.9M | $2.0M |
| Taxes Payable | $11.5M | $14.4M | $21.9M |
| Other Current Liab | $4.0M | $1.9M | $7.1M |
| Long-Term Liabilities | $30.7M | $76.3M | $79.4M |
| LT Operating Leases | $4.2M | $8.5M | $7.5M |
| Other LT Liab | $26.5M | $67.9M | $71.9M |
| Total Liabilities | $57.2M | $107.2M | $128.1M |
| Shareholders' Equity | $95.0M | $88.9M | $78.9M |
| Paid-In Capital | $142.4M | $171.1M | $173.4M |
| Retained Earnings | $-83.9M | $-100.0M | $-112.1M |
| Total L&E | $152.2M | $196.1M | $207.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $13.6M | $-16.0M | $-12.1M |
| Non-Cash Adjustments | $-19.4M | $15.7M | $-1.5M |
| Working Capital Changes | $13.1M | $8.3M | $20.4M |
| Cash from Operations | $7.3M | $7.9M | $6.8M |
| Capital Expenditures | $12.1M | $20.1M | $12.0M |
| Cash from Investing | $-26.2M | $-26.0M | $-17.1M |
| Cash from Financing | $-1.0M | $23.0M | $3.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-19.9M | $4.9M | $-7.4M |
| Beginning Cash | $29.7M | $9.7M | $14.6M |
| Ending Cash | $9.7M | $14.6M | $7.3M |
Frequently Asked Questions
How does MARIMED INC. make money?
Specialized pharmaceuticals targeting inflammatory conditions, including ulcerative colitis; proprietary research and development of next-generation biologics; strategic licensing or partnership revenue streams supporting clinical trials.
What are the main risks for MRMD?
Significant net losses of $12.1M in 2024 and a retained earnings deficit of $112.1M indicating cash burn concerns; heavy reliance on successful clinical trial outcomes given the -17.1M investing cash flow; potential regulatory hurdles in competitive biopharma markets.
What is MRMD's competitive advantage?
Differentiated pipeline of novel mechanisms of action for difficult-to-treat inflammatory diseases; established manufacturing infrastructure requiring $12M in recent capex to support scalability; potential for high-margin product launches once regulatory approvals are secured.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.